{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:38:33Z","timestamp":1779262713558,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ejphar.2014.10.037","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T15:04:41Z","timestamp":1414681481000},"page":"234-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics"],"prefix":"10.1016","volume":"745","author":[{"given":"Andrew M.","family":"Swensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wende","family":"Niforatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"McGaraughty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.10.037_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1124\/jpet.110.166363","article-title":"Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker","volume":"334","author":"Abbadie","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.10.037_bib2","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1523\/JNEUROSCI.0307-07.2007","article-title":"Differential role of N-type calcium channel splice isoforms in pain","volume":"27","author":"Altier","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2014.10.037_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1085\/jgp.81.5.613","article-title":"Lidocaine block of cardiac sodium channels","volume":"81","author":"Bean","year":"1983","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/mol.109.058834","article-title":"Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels","volume":"77","author":"Berecki","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0028-3908(95)00078-K","article-title":"Characteristics of a human N-type calcium channel expressed in HEK293 cells","volume":"34","author":"Bleakman","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2014.10.037_bib6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0022-3565(25)21283-6","article-title":"Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain","volume":"279","author":"Bowersox","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.10.037_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","article-title":"Structure and regulation of voltage-gated Ca2+ channels","volume":"16","author":"Catterall","year":"2000","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/adt.2008.136","article-title":"A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors","volume":"6","author":"Dai","year":"2008","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0006-8993(95)01447-0","article-title":"Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons","volume":"712","author":"Evans","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2014.10.037_bib10","doi-asserted-by":"crossref","first-page":"20171","DOI":"10.1074\/jbc.M300581200","article-title":"Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA","volume":"278","author":"Feng","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.10.037_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0006-8993(94)90398-0","article-title":"Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (w-conopeptide MVIIC)","volume":"653","author":"Gohil","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2014.10.037_bib12","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1152\/jn.00048.2004","article-title":"Alternative splicing in the voltage-sensing region of N-Type CaV2.2 channels modulates channel kinetics","volume":"92","author":"Lin","year":"2004","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/1568007043336743","article-title":"Voltage-gated calcium channels as targets for the treatment of chronic pain","volume":"3","author":"McGivern","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.ejphar.2014.10.037_bib14","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2174\/0929867043363884","article-title":"Ziconotide: neuronal calcium channel blocker for treating severe chronic pain","volume":"11","author":"Miljanich","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2014.10.037_bib15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.bmcl.2010.01.008","article-title":"Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors","volume":"20","author":"Pajouhesh","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2014.10.037_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-0102(02)00017-2","article-title":"Effects of ablation of N- and R-type Ca(2+) channels on pain transmission","volume":"43","author":"Saegusa","year":"2002","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejphar.2014.10.037_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bcp.2011.10.019","article-title":"A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats","volume":"83","author":"Scott","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1602\/neurorx.2.4.662","article-title":"Targeting chronic and neuropathic pain: the N-type calcium channel comes of age","volume":"2","author":"Snutch","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ejphar.2014.10.037_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2014.10.037_bib20","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1523\/JNEUROSCI.17-09-03002.1997","article-title":"Preferential interaction of omega-conotoxins with inactivated N-type Ca2+ channels","volume":"17","author":"Stocker","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2014.10.037_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/mol.111.075226","article-title":"Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels","volume":"81","author":"Swensen","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib22","doi-asserted-by":"crossref","DOI":"10.1089\/adt.2011.437","article-title":"An automated electrophysiological assay for differentiating Ca(V)2.2 inhibitors based on state dependence and kinetics","author":"Swensen","year":"2012","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00011-011-0322-9","article-title":"Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels","volume":"60","author":"Vortherms","year":"2011","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejphar.2014.10.037_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(99)00197-9","article-title":"Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain","volume":"84","author":"Wang","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2014.10.037_bib25","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1523\/JNEUROSCI.18-16-06319.1998","article-title":"Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals","volume":"18","author":"Westenbroek","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2014.10.037_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bcp.2005.04.035","article-title":"Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain","volume":"70","author":"Winquist","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.10.037_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/156802609788317838","article-title":"Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke","volume":"9","author":"Yamamoto","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"issue":"387","key":"10.1016\/j.ejphar.2014.10.037_bib28","first-page":"e381","article-title":"Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models","volume":"15","author":"Zhu","year":"2014","journal-title":"J. Pain."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914007444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914007444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:20:28Z","timestamp":1757974828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914007444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":28,"alternative-id":["S0014299914007444"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.10.037","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}